SynBioBeta Speaker

Daniel Georgiev

Sampling Human

CEO & Co-founder

Daniel Georgiev is the founder of Sampling Human, building AI-native, single-cell omics systems that turn complex human biology into scalable, actionable data for the next generation of precision medicine.

Sessions Featuring

Daniel

This Year

Breakout Session

•

4:30 PM

-

5:15 PM

AIxBIO

The Data Reality Check: Human-First Biology for AI Models

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Featuring

Andrei Georgescu

Vivodyne

CEO

Johnny Yu

Tahoe Therapeutics

CSO & Co-founder

Avantika Lal

Genentech

Principal ML Scientist II

Building DNA foundation models that design regulatory sequences.

Daniel Georgiev

Sampling Human

CEO & Co-founder

Krish Ramadurai

AIX Ventures

Partner

TechBio investor backing AI-designed drugs and breakthroughs.

Breakout Session

•

4:30 PM

-

5:15 PM

AIxBIO

The Data Reality Check: Human-First Biology for AI Models

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Featuring

Andrei Georgescu

Vivodyne

CEO

Johnny Yu

Tahoe Therapeutics

CSO & Co-founder

Avantika Lal

Genentech

Principal ML Scientist II

Building DNA foundation models that design regulatory sequences.

Daniel Georgiev

Sampling Human

CEO & Co-founder

Krish Ramadurai

AIX Ventures

Partner

TechBio investor backing AI-designed drugs and breakthroughs.

Previous Speakers Include